Dxevo (dexamethasone)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Dexamethasone is a synthetic glucocorticoid.

Dexamethasone is used principally as an anti-inflammatory or immunosuppressant agent. Because it has only minimal mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If dexamethasone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.

Generic name: dexamethasone
Pronunciation: (dex-uh-METH-uh-sown)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Dxevo

Intelligence content is not available yet.

Indications

The following indications are listed for Dxevo:

  • Acquired Thrombocytopenia
  • Acute Exacerbation Of Multiple Sclerosis
  • Acute Gouty Arthritis
  • Acute Lymphoid Leukemia
  • Acute Rheumatic Carditis
  • Adrenocortical Insufficiency
  • Adrenogenital Disorder
  • Angioedema
  • Ankylosing Spondylitis
  • Asthma Exacerbation
  • Atopic Dermatitis
  • Autoimmune Hemolytic Anemia
  • Berylliosis
  • Burkitt's Lymphoma
  • Bursitis
  • Cerebral Edema
  • Contact Dermatitis
  • Crohn's Disease
  • Dermatitis Herpetiformis
  • Diagnostic Test For Cushing's Syndrome
  • Diamond Blackfan Anemia
  • Diffuse Large B-Cell Lymphoma
  • Disseminated Tuberculosis
  • Epicondylitis
  • Erythema Multiforme
  • Erythroblastic Anemia
  • Exfoliative Dermatitis
  • Follicular Lymphoma
  • Giant Cell Arteritis
  • Hodgkin's Lymphoma
  • Humoral Hypercalcemia Of Malignancy
  • Hypersensitivity Drug Reaction
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Bowel Disease
  • Juvenile Idiopathic Arthritis
  • Laryngeal Edema
  • Loffler Syndrome
  • Mycosis Fungoides
  • Nephrotic Syndrome
  • Non-Hodgkin's Lymphoma
  • Ocular Inflammation
  • Ophthalmia Sympathetic
  • Organ Transplant Rejection
  • Pemphigus
  • Progressive Diffuse Large B-Cell Lymphoma
  • Psoriasis
  • Psoriatic Arthritis
  • Pure Red Cell Aplasia
  • Rheumatoid Arthritis
  • Sarcoidosis
  • Serum Sickness
  • Severe Persistent Asthma
  • Subacute Bursitis
  • Synovitis Due To Osteoarthritis
  • Systemic Dermatomyositis
  • Systemic Lupus Erythematosus
  • Thyroiditis
  • Transfusion Reaction Urticaria
  • Trichinosis
  • Tuberculosis Meningitis Treatment Adjunct
  • Ulcerative Colitis
  • Uveitis

Also known as: Aase Syndrome, Acquired Hemolytic Anemia Due To Antibodies, Acute Articular Gout, Acute Exacerbation Of Ms, Acute Gout Attack, Acute Gout Flare, Acute Lymphatic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphogenous Leukemia, Acute Relapse Of Ms, Acute Relapse Of Multiple Sclerosis, Acute Uratic Arthritis, Adrenal Cortical Hypofunction, Adrenal Failure, Adrenal Insufficiency, Adrenocortical Hypofunction, Adrenogenital Syndrome, Aggravation Of Asthma, Allergic Reaction To Blood Or Plasma, Allergic Transfusion Reaction, Anemia Lymphatica, Angioneurotic Edema, Arthritis Deformans, Arthrosis Deformans, Atopic Eczema, Atrophedema, Axial Spondyloarthritis With Radiographic Sacroiliitis, Bannister's Disease, Bekhterev's Arthritis, Bekhterev's Disease, Bekhterev's Spondylitis, Besnier-Boeck-Schaumann Disease, Besnier-Boeck-Schaumann Syndrome, Blackfan Diamond Syndrome, Blistering Skin Disease, Boeck's Disease, Boeck's Sarcoid, Brain Edema, Bullous Dermatitis Herpetiformis, Burkitt's Tumor, Colitis Ulcerativa, Congenital Erythroid Hypoplastic Anemia, Congenital Hypoplastic Anemia, Congenital Pure Red Cell Aplasia, Constitutional Erythroid Hypoplasia, Cranial Arteritis, Deficiency In Bone Marrow Erythroblasts, Dermatitis Venenata, Diagnostic Procedure For Cushing's Syndrome, Disseminated Lupus Erythematosus, Disseminated Neurodermatitis, Drug Hypersensitivity Reaction, Drug-Induced Hypersensitivity, Drug-Induced Hypersensitivity Reaction, Erythema Exfoliativa, Erythema Polymorphe, Erythroblastopenia, Erythroderma Exfoliativa, Erythrogenesis Imperfecta, Exacerbation Of Asthma, Exfoliative Eczema, Exfoliative Erythroderma, Extracranial Arteritis, Follicular B-Cell Lymphoma, Follicular B-Cell Non-Hodgkin's Lymphoma, Giant Urticaria, Giant-Cell Arteritis, Granulomatous Arteritis, Hebra's Disease, Herpes Iris, Hodgkin's Disease, Horton's Arteritis, Hypercalcemia Associated With Cancer, Hypercalcemia Associated With Malignancy, Hypercalcemia Of Malignancy, Hypoadrenalism, Hypocorticoidism, Immune Thrombocytopenia, Immune Thrombocytopenia Purpura, Juvenile Ra, Juvenile Rheumatoid Arthritis, Loeffler Syndrome, Loffler's Syndrome, Lupus Erythematosus Syndrome, Lymphoblastic Leukemia, Malignant Hypercalcemia, Marie-Strumpell Disease, Marie-Strumpell Spondylitis, Miliary Tuberculosis, Milton's Disease, Multiple Sclerosis Exacerbation, Nodose Rheumatism, Non-Hodgkin's Type Lymphoma, Ophthalmic Inflammation, Organ Transplant Rejection Reaction, Periodic Urticaria, Pie Syndrome, Post Infectious Thrombocytopenia, Psoriasis Arthropica, Psoriatic Arthropathy, Purpura Hemorrhagica, Quincke's Disease, Quincke's Edema, Regional Enteritis, Regional Ileocolitis, Rheumatic Arthritis, Rheumatic Gout, Rheumatoid Spondylitis, Rhizomelic Spondylitis, Rhizomelic Spondylosis, Schaumann's Syndrome, Secondary Thrombocytopenia, Serum Sickness-Like Reaction, Simple Pulmonary Eosinophilia, Spondylosis Deformans, Strumpell-Marie Disease, Suprarenal Failure, Sympathetic Ophthalmia, Synovitis Due To Oa, Synovitis With Osteoarthritis, Temporal Arteritis, Transplant Rejection, Trichinella Spiralis Infection, Trichinellosis, Trichiniasis, Urticaria Tuberosa, Urticarial Transfusion Reaction, Werlhof's Disease.

Dosing

The route of administration and dosage of dexamethasone and its derivatives depend on the condition being treated and the response of the patient. IM or IV therapy is generally reserved for patients who are not able to take the drugs orally or for use in an emergency situation. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to dosage indicated by age, body weight, or body surface area. After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response, and the drug should be discontinued as soon as possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). Following long-term therapy, dexamethasone should be withdrawn gradually. (See the Corticosteroids General Statement 68:04.)

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data